Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Clinical Study to Investigate the Safety and Pharmacokinetics of Tucatinib (MK-7119) in China Participants With HER2+ Advanced Breast Cancer, Gastric or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer

NCT05382364 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT05382364
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05382364 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Clinical Study to Investigate the Safety and Pharmacokinetics of Tucatinib (MK-7119) in China Participants With HER2+ Advanced Breast Cancer, Gastric or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer
Lead sponsor
Pfizer
Phase
Phase 1
Overall status
Active, not recruiting
Start date
June 29, 2022
Completion date
December 31, 2026
Enrollment
25 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasms, colorectal cancer, gastric or gastroesophageal junction adenocarcinoma (gec), metastatic her2+ advanced breast cancer